ClinicalTrials.gg
Active, not recruitingNCT05512390Updated Aug 28, 2026

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

A Phase 1 interventional study of ABBV-319 in Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia and Follicular Lymphoma, sponsored by AbbVie. Active, not recruiting at 20 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie — 2 open to participants now, 5 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · AbbVie.

Enrollment
7th of 10
39 · median 58
Started
2023
with 1 other
Phase 1
6 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 6 in phase 1, and was the 8th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

2 of the 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie, or all of them as a file.
02

Study summary

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), or R/R CLL. Adverse events will be assessed.

ABBV-319 is an investigational drug being developed for the treatment of R/R DLBCL, R/R FL, or R/R CLL. This study will include a dose escalation phase to determine the doses of ABBV-319 that will be used in the next phase and a dose expansion phase to determine the change in disease activity in participants with R/R DLBCL, R/R FL, and R/R CLL. Approximately 154 adult participants with R/R B cell lymphomas including R/R DLBCL, R/R FL, and R/R CLL will be enrolled in the study in sites world wide.

In the Dose Escalation phase of the study participants will receive escalating intravenously infused doses of ABBV-319 in 21-day cycles, until the Phase 2 dose is determined. In the dose expansion phase of the study participants receive intravenously infused ABBV-319 in 21-day cycles.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Follicular Lymphoma

Keywords

  • Diffuse Large B-Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Follicular Lymphoma
  • Cancer
  • B-Cell Malignancies
  • ABBV-319
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For dose escalation (Part 1) only: Participants with documented diagnosis of B-cell including those with histology based on criteria established by the World Health Organization (WHO), and requiring treatment, as per the protocol.
  • For the diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and Chronic lymphocytic leukemia (CLL) dose expansion cohorts (Part 2) only: Participants with documented diagnosis of one of the B-cell malignancies noted in the protocol with histology based on criteria established by the WHO, and measurable disease requiring treatment, as per the protocol.
  • Laboratory values meeting the criteria noted in the protocol.
  • For participants previously treated with a CD19-targeting therapy (eg, CD19 monoclonal antibody) a core or excision tumor subsequent to the most recent CD19-targeting therapy must be collected.
  • Participant must have measurable disease, as defined by the 2014 Lugano Classification.

Exclusion criteria

Exclusion Criteria:

  • Known active central nervous system (CNS) disease, or primary CNS lymphoma.
  • Known active infection or uncontrolled conditions as per the protocol.
  • (ECOG) performance status >= 2.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Dose Escalation ABBV-319

    Participants with relapsed or refractory (R/R) B cell lymphomas including diffuse large b-cell lymphoma (DLBCL) or follicular lymphoma (FL), and Chronic lymphocytic leukemia (CLL) will receive escalating doses of ABBV-319 in 21-day cycles, until the doses of ABBV-319 that will be used in the next phase are determined.

    Drug: ABBV-319

  • Experimental
    (ABBV-319) Diffuse Large B-cell Lymphoma (DLBCL) Participants

    Participants with R/R DLBCL will receive ABBV-319 in 21-day cycles.

    Drug: ABBV-319

  • Experimental
    (ABBV-319) Follicular Lymphoma (FL) Participants

    Participants with R/R FL will receive ABBV-319 in 21-day cycles.

    Drug: ABBV-319

  • Experimental
    (ABBV-319) Chronic Lymphocytic Leukemia (CLL) Participants

    Participants with R/R CLL will receive ABBV-319 in 21-day cycles.

    Drug: ABBV-319

Interventions

  • DrugABBV-319

    Intravenous (IV); Infusion

06

What researchers measure

Primary outcomes

  1. Number of Dose-Limiting Toxicities (DLT)

    A DLT is defined as any adverse event (AE) for which a clear alternative cause cannot be established (eg, attributed to the disease under study, another disease, or to a concomitant medication by the study investigators or medical monitor).

    Time frame: Day 42

  2. Number of Participants with Adverse Events (AE)

    AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 30 Months

  3. Maximum Observed Serum Concentration (Cmax) of ABBV-319

    Maximum observed serum concentration of ABBV-319.

    Time frame: Up to 6 Months

  4. Time to Cmax (Tmax) of ABBV-319

    Time to Cmax of ABBV-319.

    Time frame: Up to 6 Months

  5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-319

    Terminal phase elimination half-life of ABBV-319.

    Time frame: Up to 6 Months

  6. Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-319

    Area under the serum concentration versus time curve (AUC) of ABBV-319.

    Time frame: Up to 6 Months

  7. Antidrug Antibody (ADA)

    Incidence and concentration of anti-drug antibodies.

    Time frame: Up to 6 Months

Secondary outcomes

  1. Number of Participants with Response of Partial Response (PR) or Better per Disease-Specific Criteria

    Number of participants with response of PR or better per disease-specific criteria.

    Time frame: Up to 6 Months

  2. Duration of Response (DOR)

    DOR is defined for participants achieving a complete response (CR)/PR as the time from the initial response per investigator review to disease progression or death of any cause, whichever occurs earlier.

    Time frame: Up to 6 Months

  3. Time to Response

    Time to response is defined for participants achieving a CR/PR as the time from starting therapy to first a CR/PR.

    Time frame: Up to 6 Months

  4. Progression Free Survival (PFS) Time

    PFS is defined as time from first study treatment to a documented disease progression as determined by the investigator, or death due to any cause, whichever occurs earlier.

    Time frame: Up to 30 Months

  5. Overall survival (OS) Time

    OS is defined as time from first study treatment to death due to any cause.

    Time frame: Up to 30 Months

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Feb 2027, 46 months after the start.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's planned 46 months is close to that.

Counting every sponsor, half of 195 studies reached it within 53 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 23, 2022
StartActual
Apr 26, 2023
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05512390
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 23, 2022
Start date
Apr 26, 2023
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 28, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion